MOP Reduction During Long-Term Methamphetamine Withdrawal was Restored by Chronic Post-Treatment with Fluoxetine

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Previous research indicated fluoxetine reduces methamphetamine preference in mice.
• The impact of fluoxetine on established methamphetamine preference and drug-induced gene expression changes remained largely unexplored.

Purpose of the Study:

• To investigate the effects of fluoxetine post-treatment on methamphetamine dependence and gene expression following extended withdrawal periods in mice.
• To determine if fluoxetine could reverse methamphetamine-induced conditioned place preference and normalize altered gene expression in the frontal cortex.

Main Methods:

• Mice received chronic methamphetamine treatment followed by withdrawal, with some receiving fluoxetine post-treatment.
• Gene expression analysis was conducted on frontal cortex mRNA using a custom cDNA array and real-time quantitative reverse transcription-PCR.
• Western blot analyses confirmed changes in protein levels.

Main Results:

• Chronic fluoxetine post-treatment effectively abolished methamphetamine-conditioned place preference.
• Long-term withdrawal from methamphetamine significantly reduced mu-opioid receptor (MOP) gene expression in the frontal cortex.
• Fluoxetine administration restored the reduced MOP gene expression and protein levels.

Conclusions:

• Fluoxetine post-treatment demonstrates efficacy in reversing methamphetamine-associated behaviors.
• Fluoxetine may be a viable therapeutic strategy for restoring MOP levels in the frontal cortex during methamphetamine abstinence.
• These findings highlight fluoxetine's potential role in mitigating long-term neurobiological consequences of methamphetamine use.